Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics | Zendy

Dagmar F. Hernández-Suárez | Zendy; Stuart A. Scott | Zendy; Matthew I. Tomey | Zendy; Kyle Melín | Zendy; Angel LópezCandales | Zendy; Charlotte E. Buckley | Zendy; Jorge Ducongé | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics

Author(s) -

Dagmar F. Hernández-Suárez,

Stuart A. Scott,

Matthew I. Tomey,

Kyle Melín,

Angel LópezCandales,

Charlotte E. Buckley,

Jorge Ducongé

Publication year - 2017

Publication title -

therapeutic advances in cardiovascular disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.164

H-Index - 33

eISSN - 1753-9455

pISSN - 1753-9447

DOI - 10.1177/1753944717718718

Subject(s) - medicine , clopidogrel , prasugrel , ticagrelor , odds ratio , coronary artery disease , p2y12 , cohort , cardiology , aspirin

Clopidogrel is by far the most prescribed platelet adenosine diphosphate (ADP) antagonist in Puerto Rico despite the advent of newer agents (prasugrel and ticagrelor). Given the paucity of data on clopidogrel responsiveness in Hispanics, we sought to determine the association between clinical characteristics and platelet reactivity in Puerto Rican patients on clopidogrel therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research